Endpoint
Waist-to-hip ratio
The waist circumference measurement divided by the hip circumference measurement. For both men and women, a waist-to-hip ratio (WHR) of 1.0 or higher is considered at risk for undesirable health consequences, such as heart disease and ailments associated with overweight. A healthy WHR is 0.90 or less for men, and 0.80 or less for women. (National Center for Chronic Disease Prevention and Health Promotion, 2004)
CAT:outcome/waist-to-hip-ratioreported in index2 findings from 2 compounds
What moved it
How to read these marks2 findings · 2 compounds · 2 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| resveratrol | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| berberine | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Every finding here is a null result.
Measured, no effect detected
2 findings
resveratrol — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The result indicated that there was just the trend of decrease but no significance after treatment with resveratrol compared with placebo in BW [SMD = − 0.08, 95% CI (−0.35, 0.18), p = 0.544], BMI [SMD = − 0.07, 95% CI (−0.33, 0.20), p = 0.633], WC [SMD = −0.73, 95% CI (−1.97, 0.51), p = 0.249] and WHR [SMD = −0.12, 95% CI (−0.40, 0.16), p = 0.405] (Supplementary Figures S14, 15).”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.. - Study
- meta-analysis
- Dose
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Effect -0.12 standardised mean difference, 95% CI -0.4 to 0.16
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.2023PMID:37767399Permalink
berberine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“However, berberine did not significantly reduce WHR compared to control groups (MD of -0.01, 95% CI: -0.03 to 0.01).”
Quoted verbatim from The effect of berberine on obesity indices: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- adults in randomized controlled trials of berberine for obesity indices
The effect of berberine on obesity indices: a systematic review and meta-analysis.2026PMID:41310257Permalink
How it is measured
Waist girth divided by hip girth from tape anthropometry at the landmarks stated by the source protocol - WHO specifies the waist at the midpoint between the lowest rib and the iliac crest and the hip at the widest gluteal circumference. The landmark convention is recorded with each finding; umbilical and narrowest-point waist conventions give different values.
Measured, not recorded
- Subject
- waist-to-hip ratio
- Measurements
- 13 measurements
- Recorded as a finding
- No
Show what was measured
Waist-to-hip ratio
no effect, p = 0.764, n = 53
WHR | 0.87 ± 0.02 | 0.87 ± 0.02 | 0.296 | 0.764 | 1.027 | 0.307 | 0.597 | 0.552
PMID:29483384 · one of two readings recorded this
Waist-to-hip ratio
decreases, p = 0.0001
significant reduction in WHR (WMD: -0.03; 95 % CI: -0.04 to -0.01, P < 0.0001)
PMID:32147051 · one of two readings recorded this
Waist-to-hip ratio
no effect, WMD -0.024 (95% CI -0.048, 0.000), p = 0.052
Compared with the control group, there was no significant difference in WHR in the intervention group (WMD -0.024, 95% CI -0.048 to 0.000, P = 0.052, I2 = 0.0%,.
PMID:36387924 · one of two readings recorded this
waist-to-hip ratio
no effect, p = 0.86
the waist-to-hip ratio (WHR) did not change significantly (P = 0.86)
PMID:40770379 · one of two readings recorded this
Waist-to-hip ratio
no effect
berberine did not significantly reduce WHR compared to control groups (MD of -0.01, 95% CI: -0.03 to 0.01)
PMID:41310257 · one of two readings recorded this
Waist-to-hip ratio
no effect
WHR (WMD: 0.00, 95% CI: -0.01 to 0.02)
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Age | ≥ 50 years | 1 | -0.01 (-0.39 to 0.37) | - | -
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Dose | 1200 mg | 2 | 0.00 (-0.01 to 0.02) | 0.0 | 0.755
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
≤ 400 mg | 1 | -0.01 (-0.39 to 0.37) | - | -
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
≤ 12 weeks | 2 | 0.00 (-0.01 to 0.02) | 0.0 | 0.755
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Follow-up | ≥ 24 weeks | 1 | -0.01 (-0.39 to 0.37) | - | -
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Diagnosis of NAFLD | Ultrasonography | 2 | 0.00 (-0.01 to 0.02) | 0.0 | 0.755
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Sample size | ≥ 50 participants | 1 | -0.01 (-0.39 to 0.37) | - | -
PMID:41917882 · one of two readings recorded this
Sources cited
2 papers
- Subject
- waist-to-hip ratio
- Findings
- 2
- Papers
- 2